
|Articles|September 1, 2006
Do lentiviral vectors hold the answer to glaucoma therapy?
Fort Lauderdale, FL-Investigators have shown for the first time in nonhuman primates that, using lentiviral vectors, it is possible to achieve good gene marker expression that is sustained and that does not cause inflammation or other side effects. The most important factor in this research with lentiviral vectors is the longevity of the expression in contrast to adenoviral vectors, according to Eric Poeschla, MD.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals
2
Meta's AI glasses for veterans: Canto-Sims, OD on closing the access gap
3
Bayer acquires Perfuse Therapeutics, partners with Iambic to expand ophthalmology and AI capabilities
4
Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease
5


























